Cytokinetics, Incorporated (CYTK): Price and Financial Metrics

Cytokinetics, Incorporated (CYTK)

Today's Latest Price: $15.49 USD

0.14 (0.91%)

Updated Oct 29 4:00pm

Add CYTK to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

CYTK Stock Summary

  • With a price/sales ratio of 57.92, Cytokinetics Inc has a higher such ratio than 96.23% of stocks in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -6.25 for Cytokinetics Inc; that's greater than it is for just 2.75% of US stocks.
  • Revenue growth over the past 12 months for Cytokinetics Inc comes in at -47.54%, a number that bests just 4.65% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Cytokinetics Inc are CLVS, CLSN, RMBS, STRO, and NVCN.
  • CYTK's SEC filings can be seen here. And to visit Cytokinetics Inc's official web site, go to

CYTK Stock Price Chart Interactive Chart >

Price chart for CYTK

CYTK Price/Volume Stats

Current price $15.49 52-week high $30.14
Prev. close $15.35 52-week low $7.72
Day low $14.89 Volume 900,400
Day high $15.75 Avg. volume 1,112,393
50-day MA $21.04 Dividend yield N/A
200-day MA $18.71 Market Cap 1.09B

Cytokinetics, Incorporated (CYTK) Company Bio

Cytokinetics, Incorporated, a clinical stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The company was founded in 1997 and is based in South San Francisco, California.

CYTK Latest News Stream

Event/Time News Detail
Loading, please wait...

CYTK Latest Social Stream

Loading social stream, please wait...

View Full CYTK Social Stream

Latest CYTK News From Around the Web

Below are the latest news stories about Cytokinetics Inc that investors may wish to consider to help them evaluate CYTK as an investment opportunity.

Cytokinetics initiates early-stage study with its second myosin inhibitor in cardiovascular disorder

Cytokinetics (CYTK) has dosed the first participants in a Phase 1 single ascending dose clinical study of CK-3772271 (CK-271), a cardiac myosin inhibitor for the potential treatment of hypertrophic cardiomyopathy ((HCM)), characterized by heart muscle (myocardium) becomes abnormally thick.The primary objective of this study is to assess the safety and tolerability of...

Seeking Alpha | September 23, 2020

Cytokinetics, HCM Registry team up to assess risk in cardiovascular disorder

Cytokinetics (CYTK) announces $1M grant and four-year partnership with the HCM Registry ((HCMR)), a global registry of patients with hypertrophic cardiomyopathy ((HCM)), an inherited cardiovascular disorder in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied).The HCMR was designed as the first multinational registry to identify novel prognostic markers in...

Seeking Alpha | August 18, 2020

Cytokinetics Reports Second Quarter 2020 Financial Results

Top-line Results from GALACTIC-HF Expected in Q4 2020 Licensing Collaboration, Royalty Monetizations and Financing Provide Additional Capitalto Support…

GlobeNewswire | August 6, 2020

Earnings Preview: Cytokinetics (CYTK) Q2 Earnings Expected to Decline

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 30, 2020

Can You Imagine How Jubilant Cytokinetics' (NASDAQ:CYTK) Shareholders Feel About Its 279% Share Price Gain?

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a...

Yahoo | July 24, 2020

Read More 'CYTK' Stories Here

CYTK Price Returns

1-mo -30.63%
3-mo -28.35%
6-mo 6.90%
1-year 30.83%
3-year 11.44%
5-year 79.91%
YTD 45.99%
2019 67.88%
2018 -22.45%
2017 -32.92%
2016 16.16%
2015 30.59%

Continue Researching CYTK

Want to see what other sources are saying about Cytokinetics Inc's financials and stock price? Try the links below:

Cytokinetics Inc (CYTK) Stock Price | Nasdaq
Cytokinetics Inc (CYTK) Stock Quote, History and News - Yahoo Finance
Cytokinetics Inc (CYTK) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8595 seconds.